CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of renal cell carcinoma.
  
  LEARNING OBJECTIVES

  • Evaluate recent data with and consider the current role of adjuvant anti-PD-1/PD-L1 antibody therapy for patients with RCC at high risk for recurrence after nephrectomy.
  • Consider evidence-based research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
  • Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel patients regarding the risks and benefits of these novel regimens.
  • Review the biologic rationale for the investigation of anti-PD-1/anti-CTLA-4/multikinase inhibitor combination therapy as first-line treatment for mRCC, and appreciate available research documenting the effectiveness of this approach.
  • Develop a logical approach to the sequencing of systemic therapies for patients with advanced RCC that has progressed on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapeutic strategies.
  • Appreciate published clinical research evaluating available and investigational agents for non-clear cell RCC, and consider the applicability of these strategies in current clinical care.
  • Recognize the side effects and toxicities commonly associated with approved and investigational therapies, and develop supportive care plans for patients with RCC undergoing treatment.
  • Recall available and emerging data with other novel and investigational agents currently being studied for RCC, and, where applicable, refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Prof Laurence Albiges, MD, PhD
  Medical Oncologist
  Chair, Medical Oncology Department
  Gustave Roussy Cancer Center
  Villejuif, France
  
  No relevant conflicts of interest to disclose.
  
  Toni K Choueiri, MD
  Director, Lank Center for Genitourinary Oncology
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  The Jerome and Nancy Kohlberg Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Thomas Powles, MBBS, MRCP, MD
  Director of Barts Cancer Centre
  Queen Mary University of London
  London, United Kingdom
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc.
  
  MODERATOR
  
  Brian Rini, MD
  Professor of Medicine
  Chief of Clinical Trials
  Vanderbilt-Ingram Cancer Center
  Division of Hematology/Oncology
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Advisory Committee and Consulting Agreements: Alkermes, Allogene Therapeutics, Aravive Inc, Arrowhead Pharmaceuticals, Athenex, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Debiopharm, Eisai Inc, EUSA Pharma, Genentech, a member of the Roche Group, Merck, NiKang Therapeutics Inc, Pfizer Inc, Sanofi, Shionogi Inc, Surface Oncology; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Surface Oncology; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Stock Options/Ownership — Public Company: PTC Therapeutics; Nonrelevant Financial Relationship: MashupMD — Podcast partnership.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck.
  
  Release date: March 2023
  Expiration date: March 2024